manop-shutterstock-com
manop / Shutterstock.com
27 January 2016AmericasJenny Shmuel and Megan Chacon

Diagnostics patent eligibility: a turning point approaches

The patent eligibility landscape under 35 USC §101 has shifted in the past few years, with the courts issuing a series of decisions which threaten to undermine a system designed to encourage and reward innovation and development. The application of this law in one particular area—screening and diagnostic testing during and after pregnancy—highlights the unprecedented difficulty faced by those seeking patent protection in the life sciences arena and points to a potential turning point in the law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 April 2026   A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.
Americas
16 April 2026   The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.
Americas
14 April 2026   A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.